AI-Designed Vaccine Shows Early Promise Against Future Viral Threats
Researchers at the University of Cambridge say they have used artificial intelligence to design a new type of vaccine that could offer broad protection against coronaviruses, including current Covid variants and related viruses found in animals that may pose future risks to humans.
The vaccine’s central component, known as an antigen, was designed entirely by AI and has now been tested in people for the first time, according to the research team. Antigens are the parts of vaccines that train the immune system to recognize and respond to infection.
Instead of basing the vaccine on a single current virus strain, the Cambridge team used genetic information from a range of coronaviruses identified through surveillance programmes. AI analysed this data and designed what researchers describe as a “super-antigen,” intended to help the immune system recognize shared features across a broader family of viruses.
The work remains at an early stage. An initial trial involving 39 people focused mainly on safety. Findings published in the Journal of Infection reported a modest immune response. A larger study involving about 200 participants is expected to provide more information about how effectively the vaccine trains the immune system.
Professor Jonathan Heeney of Cambridge said the aim is to prepare for future outbreaks before they occur, rather than responding after a virus has already begun spreading. Researchers are also exploring similar AI-designed approaches for flu, H5N1 bird flu, Ebola and other viral haemorrhagic fevers.
Independent experts have described the findings as scientifically interesting, while noting that human immune responses can differ significantly from those seen in animal studies. Professor Andy Pollard of the Oxford Vaccine Group said the main test will come from further human trials.
UK officials and researchers say AI could help accelerate vaccine development by predicting immune responses more efficiently, potentially improving preparedness for future pandemics.